An Evaluation of the Pharmacodynamics, Safety, and Tolerability of the Potassium Binder RDX7675.

In conclusion, repeated oral dosing with RDX7675 over 4 days reduced potassium absorption in healthy volunteers; the results support QD dosing of RDX7675 in future clinical studies.
PMID: 29645278 [PubMed - as supplied by publisher]

Source: The Journal of Clinical Pharmacology - April 12, 2018 Category: Drugs & Pharmacology Authors: Pitt B, Zann V, Roe C, Jacobs JW, Davidson JP, Dowd C, Kumaraswamy P, Lin F, Korner P, Blanks RC, Rosenbaum DP Tags: J Clin Pharmacol Source Type: research